Multicenter trial of naloxone in alzheimer's disease
- 1 April 1989
- journal article
- clinical trial
- Published by Wiley in Annals of Neurology
- Vol. 25 (4) , 404-406
- https://doi.org/10.1002/ana.410250413
Abstract
In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.Keywords
This publication has 10 references indexed in Scilit:
- Naloxone and Alzheimer's DiseaseArchives of General Psychiatry, 1986
- Effects of Naloxone in Treatment of Senile DementiaJournal of the American Geriatrics Society, 1985
- Lack of clinical benefit from naloxone in a dementia day hospitalAnnals of Neurology, 1984
- Brain and serum levels of naloxone following peripheral administrationLife Sciences, 1983
- High-Dose Naloxone Infusions in NormalsArchives of General Psychiatry, 1983
- Effects of Naloxone in Senile Dementia: A Double-Blind TrialNew England Journal of Medicine, 1983
- Hormonal Influences on MemoryAnnual Review of Psychology, 1983
- Potential Therapies in Aging and Senile Dementias*Annals of the New York Academy of Sciences, 1982
- Septohippocampal cholinergic neurons are regulated trans-synaptically by endorphin and corticotropin neuropeptidesJournal of Neuroscience, 1982
- Naloxone blocks the effect of 5-hydroxy-tryptophan on passive avoidance learning in rats: Implication of endogenous opioid peptidesLife Sciences, 1981